Journal of Clinical Oncology, Vol 1, 317-325, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen

WA Bleyer, PF Coccia, HN Sather, C Level, J Lukens, DJ Niebrugge, S Siegel, PS Littman, SL Leikin and DR Miller

During the period 1976-1981, 3241 children were enrolled on three major studies of acute lymphoblastic leukemia by participating institutions of the Children's Cancer Study Group. Each study included a different method of central nervous system (CNS) prophylaxis: (1) standard therapy with cranial irradiation, 2400 rads, and intrathecal methotrexate at 12 mg/m2 six times during consolidation (CCG-141); (2) a modification of CCG-141 in which the intrathecal methotrexate was initiated during induction (CCG-141A); and (3) a reduced cranial irradiation dose of 1800 rads with intrathecal methotrexate given at the same frequency as a CCG-141A, with or without maintenance intrathecal methotrexate, but with a dosage regimen derived from CNS volume considerations rather than based on body surface area (CCG-160 series). Strategy 3, a change in the intrathecal methotrexate dosage, has resulted in the lowest incidence of CNS leukemia to date (p less than 0.007). The cumulative 3-yr CNS relapse rate has decreased from 8%- 10% to 2%-5% in average-risk patients (p less than 0.02; life table estimate) and from 23%-27% to 6% in high-risk patients (p less than 0.0002; life table estimate), despite a reduction in the cranial irradiation dose from 2400 to 1800 rads. Maintenance intrathecal chemotherapy has had a marginal effect among patients randomized to receive this additional therapy (p = 0.06). The overall outcome has been an increase in the continuous complete remission rate (p = 0.04) but not in the estimated 3-yr continuous hematologic remission or survival rates.

This article has been cited by other articles:

				E. Jabbour, S. O'Brien, H. Kantarjian, G. Garcia-Manero, A. Ferrajoli, F. Ravandi, M. Cabanillas, and D. A. Thomas Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia Blood, April 15, 2007; 109(8): 3214 - 3218. [Abstract] [Full Text] [PDF]

				Y. Matloub, S. Lindemulder, P. S. Gaynon, H. Sather, M. La, E. Broxson, R. Yanofsky, R. Hutchinson, N. A. Heerema, J. Nachman, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group Blood, August 15, 2006; 108(4): 1165 - 1173. [Abstract] [Full Text] [PDF]

				G. Velez, P. Yuan, C. Sung, G. Tansey, G. F. Reed, C.-C. Chan, R. B. Nussenblatt, and M. R. Robinson Pharmacokinetics and Toxicity of Intravitreal Chemotherapy for Primary Intraocular Lymphoma Arch Ophthalmol, October 1, 2001; 119(10): 1518 - 1524. [Abstract] [Full Text] [PDF]

				S. L. Berg and D. G. Poplack Treatment of Meningeal Malignancy Oncologist, February 1, 1996; 1(1): 56 - 61. [Abstract] [Full Text] [PDF]

				H. H. Mahmoud, G. K. Rivera, M. L. Hancock, R. A. Krance, L. E. Kun, F. G. Behm, R. C. Ribeiro, J. T. Sandlund, W. M. Crist, and C.-H. Pui Low Leukocyte Counts with Blast Cells in Cerebrospinal Fluid of Children with Newly Diagnosed Acute Lymphoblastic Leukemia N. Engl. J. Med., July 29, 1993; 329(5): 314 - 319. [Abstract] [Full Text]